US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
Latest Information Update: 26 Dec 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary) ; Deoxycholic acid (Primary)
- Indications Glabellar lines; Nasolabial fold
- Focus Therapeutic Use
- Acronyms US HARMONY in DIVERSITY
- Sponsors AbbVie
Most Recent Events
- 23 Dec 2025 Planned End Date changed from 1 Jul 2026 to 1 Mar 2026.
- 23 Dec 2025 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2025 Planned number of patients changed from 100 to 130.